Comparative Pharmacology
Head-to-head clinical analysis: BINIMETINIB versus KOSELUGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BINIMETINIB versus KOSELUGO.
BINIMETINIB vs KOSELUGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binimetinib is a reversible, non-ATP-competitive allosteric inhibitor of MEK1 and MEK2, blocking downstream ERK phosphorylation and signaling in the RAS-RAF-MEK-ERK pathway.
Selective inhibitor of MEK1 and MEK2, downstream kinases in the RAS/RAF/MEK/ERK signaling pathway. Inhibits cell proliferation and induces apoptosis in tumor cells with activating mutations in BRAF or RAS.
45 mg orally twice daily.
600 mg orally twice daily on an empty stomach (at least 1 hour before or 2 hours after a meal).
None Documented
None Documented
Terminal elimination half-life is approximately 3.5–4 hours at steady state; no significant accumulation observed with twice-daily dosing.
Terminal elimination half-life is approximately 23-25 hours, supporting once-daily dosing with steady-state achieved within 5 days.
Primarily hepatic metabolism with biliary-fecal elimination; unchanged drug in urine is negligible (<1%). In mass balance studies, ~70-80% of the dose is recovered in feces (mainly as metabolites) and <20% in urine (as metabolites).
Primarily excreted via feces (94%) with minimal renal excretion (<1% unchanged in urine). Biliary excretion accounts for a minor pathway.
Category C
Category C
MEK Inhibitor
MEK Inhibitor